Clarithromycin 500 mg Tablets Under Non-Fasting Conditions
Condition: Healthy
Intervention: clarithromycin; BIAXIN®
Intervention description: 500 mg Tablet; 500 mg Tablet
Intervention MeSH terms: Clarithromycin
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 24.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      This study will compare the relative bioavailability (rate and extent of absorption) of 500
      mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1
      x 500 mg tablet) in healthy adult subjects under non-fasting conditions.
    

Eligibility criteria:

        Inclusion Criteria:

        All subjects selected for this study will be healthy men or women 18 years of age or older
        at the time of dosing. The subject's body mass index (BMI) should be less than or equal to
        30.

        Each subject will complete the screening process within 28 days prior to period I dosing.
        Consent documents for both the screening evaluation and HIV antibody determination will be
        reviewed, discussed and signed by each potential participant before full implementation of
        screening procedures.

        Screening will include general observations, physical examination, demographics, medical
        and medication history, an electrocardiogram, sitting blood pressure and heart rate,
        respiratory rate and temperature. The physical examination will include, but may not be
        limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central
        nervous systems.

        The screening clinical laboratory procedures will include:

        HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet count
        CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total
        bilirubin, total protein, and alkaline phosphatase HIV antibody, hepatitis B surface
        antigen, hepatitis C antibody screens URINALYSIS: by dipstick; full microscopic examination
        if dipstick positive URINE DRUG SCREEN: ethyl alcohol, amphetamines, barbiturates,
        benzodiazepines, cannabinoids, cocaine metabolites, opiates and phencyclidine SERUM
        PREGNANCY SCREEN (female subjects only) FOLLICLE STIMULATING HORMONE (FSH; female subjects
        only): verify postmenopausal status

        If female and :

        is postmenopausal for at least 1 year; or is surgically sterile (bilateral tubal ligation,
        bilateral oophorectomy, or hysterectomy).

        Exclusion Criteria:

        Subjects with a recent history of drug or alcohol addiction or abuse. Subjects with the
        presence of a clinically significant disorder involving the cardiovascular, respiratory,
        renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or
        psychiatric disease (as determined by the clinical investigators).

        Subjects whose clinical laboratory test values are outside the accepted reference range and
        when confirmed on re-examination are deemed to be clinically significant.

        Subjects demonstration a positive hepatitis B surface antigen screen, hepatitis C antibody
        screen or a reactive HIV antibody screen.

        Subjects demonstrating a positive drug abuse screen when screened for this study.

        Female subjects who are currently breast feeding. Female subjects who are demonstrating a
        positive pregnancy screen. Subjects with a history of allergic response(s) to
        Clarithromycin or related drugs.

        Subjects with a history of clinically significant allergies including drug allergies.

        Subjects with a clinically significant illness during the 4 weeks prior to Period I dosing
        (as determined by the clinical investigators).

        Subjects who currently use or reports using tobacco or nicotine-containing products within
        90 days prior to Period I dosing.

        Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in the
        30 days prior to Period I dosing.

        Subjects who report donating greater than 150 mL of blood within 30 days prior to Period I
        dosing. All subjects will by advised not to donate blood for four weeks after completing
        the study.

        Subjects who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I
        dosing. All subjects will be advised not to donate plasma for four weeks after completing
        the study.

        Subjects who report receiving any investigational drug within 30 days prior to Period I
        dosing.

        Subjects who report taking any prescription medication in the 14 days prior to Period I
        dosing, with the exception of topical products without systemic absorption.

        Subjects who have been on an abnormal diet during the 28 days prior to Period I dosing.

        Subjects who report an intolerance of direct venipuncture.